Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : Invizius
Deal Size : Undisclosed
Deal Type : Agreement
Aptamer Group Partners with Invizius to Develop Next-Gen Complement System Therapies
Details : Aptamer will develop Optimer binders targeted to critical factors of the complement system and will help suppress unwanted immune responses in multiple diseases, including IgA nephropathy.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
September 02, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : Invizius
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : AST-201
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptamer Sciences Files IND Application for AST-201, an Innovative Liver Cancer Treatment
Details : AST-201 is an aptamer-drug conjugate designed to target GPC3 protein, which exhibits high expression levels in specific cancer cells. It is being evaluated for the treatment of liver cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : AST-201
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptamer and PinotBio Collaborate on Drug Conjugates for Targeted Drug Delivery
Details : The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 03, 2021
Reset All
